# Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers

> **NCT05102136** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 56 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** REGN9933
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05102136
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-27
- **Primary completion:** 2023-04-04
- **Final completion:** 2023-04-04
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2023-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05102136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05102136, "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05102136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*